



**Perceptronix**  
Early diagnosis, better outcomes™

## **PRESS RELEASE**

*For immediate release*

### **PERCEPTRONIX RAISES CDN\$5.5M**

**VANCOUVER, CANADA (June 20, 2006)** – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver based cancer diagnostics company, announced today that it has recently raised CDN\$5.5 M in private financing designed to serve as a bridge to an anticipated larger institutional private placement financing.

“This is a very exciting time in the life of Perceptronix which is now in transition from development to commercialization, having received regulatory approvals for a number of our products in North America and Europe in the past 4 months,” said Milton Wong, Perceptronix Chairman and CEO. “The successful bridge funding combined the support of new investors with the continued demonstrated support of the British Columbia Investment Management Corporation and individual investors, all of whom are excited by the Perceptronix story. The follow-on private placement will capitalize the company for effective rapid commercialization of our cancer diagnostic products and laboratory services.”

#### **About Perceptronix Medical Inc. ([www.perceptronix.com](http://www.perceptronix.com))**

Perceptronix is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

The Perceptronix goal is to develop and commercialize a suite of technologies and laboratory services to approach cancer diagnosis comprehensively: early detection, localization, diagnosis and follow-up. The first of Perceptronix’s technologies to receive regulatory approvals are:

- The **ClearSign™** Sputum Test for early lung cancer detection. This test is highly tolerated, inexpensive, radiation free and potentially widely available because it does not require interpretation by a specialist such as a radiologist. It received **CE** Mark registration in Q2, 2006 and a license application is currently under review by Health Canada,
- The **ClearCyte™** Test is used to measure “gross genomic aberrations” (DNA Ploidy). It has a Health Canada license and received **CE** Mark registration in Q1, 2006, and
- The **Clear2C™** quantitative DNA staining kit which received a Health Canada license, **CE** Mark registration and US Food & Drug Administration Medical Device Listing in early 2006.

The Perceptronix **Clinical Quantitative Cytology Laboratory** in Vancouver, Canada, currently offers the **ClearCyte™** Test to assist clinicians in the diagnosis and prognosis of cancer and will offer the **ClearSign™** Sputum Test once the Health Canada license is received.



The Perceptronix product pipeline also includes **ClearVu™** and **ClearVu™ Elite** simultaneous and spectral fluorescence/white light endoscopy systems, and **ClearPath™**, an aid to definitive diagnosis of biopsy sections.

**Contact:**

Susan Grose  
Corporate Secretary  
Perceptronix Medical Inc.  
Ste. 400, 555 West 8<sup>th</sup> Avenue  
Vancouver, Canada V5Z 1C6  
Phone: (604) 707 – 9037  
[info@perceptronix.com](mailto:info@perceptronix.com)